[Blog] FDA Introduces 12-Digit NDC Format: Operational and Serialization Implications for the Pharma Supply Chain
Table of Contents
FDA introduces a standardized 12-digit NDC format
Pharmaceutical companies are preparing for multiple regulatory milestones under the U.S. Drug Supply Chain Security Act (DSCSA). Alongside these requirements, the U.S. Food and Drug Administration (FDA) has introduced another structural change that will affect how medicines are identified, labeled, and managed across digital systems.
The agency has finalized the rule “Revising the National Drug Code Format and Drug Label Barcode Requirements,” confirming the transition to a standardized 12-digit National Drug Code (NDC) format.
Although the transition timeline extends over several years, the update will influence product labeling, master data management, serialization environments, and regulatory reporting processes across the pharmaceutical supply chain.
Manufacturers, CDMOs, repackagers, and logistics partners should begin assessing the operational and technical implications early.
The FDA has finalized a rule introducing a standardized 12-digit National Drug Code (NDC) format for drugs marketed in the United States. The change will affect pharmaceutical labeling, product master data, serialization systems, and regulatory reporting workflows across the supply chain. Companies must prepare their systems and operational processes before the full transition deadline in 2033.
Why the NDC Format Is Changing
- Human drugs, including biologics
- Animal drugs
- FDA-assigned NDC identifiers
The update does not affect the HIPAA 11-digit reimbursement format used for billing and claims processing.
A standardized structure is expected to simplify system integration and improve consistency across regulatory and supply chain data environments.
Implementation Timeline
The FDA has established a phased transition period to allow the industry to update systems and operational processes.
2026 – 2033 | Preparation Period
During this period, the FDA will continue assigning 10-digit NDCs, giving companies time to evaluate the impact on internal infrastructure and operational workflows.
Organizations should review potential implications for:
- Product master data structures
- Packaging and labeling processes
- Serialization and traceability platforms
- Integration with regulatory reporting systems
Early preparation will help reduce operational risk as the industry moves toward the new format.
March 7, 2033 | Effective Date
Starting on this date:
- The FDA will assign only 12-digit NDCs
- Existing 10-digit NDCs will be converted to the new format
- Systems and labeling must support the 12-digit structure
March 7, 2033 – March 6, 2036 | Labeling Transition Period
The FDA will allow a three-year transition period for companies to update labeling and packaging materials.
During this time:
- The agency does not intend to object to continued use of 10-digit NDCs on labeling
- Companies should begin implementing 12-digit NDCs as soon as feasible
After March 7, 2036, products entering interstate commerce with 10-digit NDC labels may be subject to regulatory enforcement.
Operational Impact for Pharmaceutical Companies
Manufacturers will need to revise product labeling to reflect the new format. In many cases, this involves adding leading zeros to existing codes and updating packaging artwork.
Key considerations include:
- Updating labeling for all marketed products
- Managing legacy label inventory during the transition
- Coordinating packaging updates across multiple SKUs and markets
- Reviewing validation requirements for packaging line changes
Enterprise Data Management
The NDC format change also affects how product identifiers are stored and exchanged across enterprise systems.
Organizations should assess the impact on:
- ERP systems
- Warehouse management systems
- Government reporting interfaces
- Data warehouses and analytics platforms
For many companies, the change will require updates to database structures, validation rules, and data exchange formats.
Serialization and Traceability Systems
NDC identifiers are commonly embedded within serialization hierarchies and product master data supporting DSCSA compliance.
As a result, serialization environments may require configuration updates across:
- Product master data models
- Serialization event data mapping
- EPCIS reporting workflows
- Partner data exchange interfaces
Companies operating multi-site production networks or complex partner ecosystems should also ensure alignment with CDMOs, repackagers, and logistics providers.
Exceptions
Key Questions Companies Should Ask Now
Although the full transition timeline extends over the next decade, organizations should begin evaluating readiness across their supply chain and IT environments.
Key questions to consider include:
Are our internal systems ready to store and process 12-digit NDCs?
ERP systems, serialization platforms, and reporting interfaces may require adjustments to database fields and validation logic.
How is the NDC used within our serialization architecture?
Companies should review how NDC identifiers are embedded in serialization hierarchies, EPCIS events, and partner data exchanges.
What is the impact on labeling and packaging workflows?
Packaging artwork, line documentation, and product specifications will need to reflect the updated format.
Are our external partners aligned with the transition?
CDMOs, repackagers, and logistics providers may operate different data standards and systems.
Do we have a coordinated plan for managing the data transition?
Successful implementation requires collaboration between regulatory, IT, packaging, and supply chain teams.
SoftGroup Insight: Why Early System Readiness Matters
The transition to a 12-digit NDC format is fundamentally a data structure update, but its operational impact extends across multiple digital systems supporting pharmaceutical supply chains.
Within many organizations, NDC identifiers are embedded in:
- Product master data records
- Serialization hierarchies
- EPCIS event reporting structures
- Regulatory reporting workflows
Updating the NDC format therefore requires coordination between regulatory teams, packaging operations, IT departments, and external partners.
Organizations that evaluate system readiness early can reduce the risk of data inconsistencies, integration issues, and production disruptions during the transition period.
As pharmaceutical supply chains become increasingly digital and interconnected, maintaining well-structured product data and interoperable traceability systems remains essential for long-term compliance.